Permeon Biologics Inc.

Permeon(TM) Biologics Announces the Appointment of Katherine S. Bowdish, Ph.D., as President and Chief Scientific Officer

Permeon(TM) Biologics Announces the Appointment of Katherine S. Bowdish, Ph.D., as President and Chief Scientific Officer

February 23, 2012

CAMBRIDGE, Mass., Feb 23, 2012 (BUSINESS WIRE) -- Permeon(TM) Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the appointment of Katherine S. Bowdish, Ph.D., as president and chief scientific officer. Dr. Bowdish also joins the Permeon board of directors. Previously, Dr. Bowdish was the co-founder, president and chief executive officer of Anaphore, a platform-based drug development company pioneering Atrimers(TM), a new class of trivalent protein pharmaceuticals.

Mascoma Corporation

Mascoma Announces FDA Favorable Review of Drop-In MGT™ Yeast Product

Mascoma Announces FDA Favorable Review of Drop-In MGT™ Yeast Product

February 22, 2012

Lebanon, New Hampshire – February 22, 2012 – Mascoma Corporation, a renewable fuels company, announced today that the U.S. Food and Drug Administration’s (FDA) Center for Veterinary Medicine has completed its scientific review and supports the use of the Mascoma Grain Technology, or MGT™, yeast product as a processing aid in the production of animal feed, which is a by-product of the corn ethanol conversion process.

Receptos, Inc.

Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science

Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science

February 16, 2012

SAN DIEGO, Feb. 16, 2012 /PRNewswire via COMTEX/ -- Receptos Inc. announced today the publication of key results relating to its expertise in S1P1 biology and structure-based drug discovery for high-value G-protein-coupled receptor (GPCR) targets in Science.

Tetraphase Pharmaceuticals, Inc.

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

February 16, 2012

WATERTOWN, Mass., Feb 16, 2012 (BUSINESS WIRE) -- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens and the lead product

Quanterix to Collaborate With the Forsyth Institute and Beth Israel Deaconess Medical Center to Develop Tuberculosis Test

Quanterix to Collaborate With the Forsyth Institute and Beth Israel Deaconess Medical Center to Develop Tuberculosis Test

February 9, 2012

CAMBRIDGE, MA – February 9, 2012 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it will apply its cutting-edge technology towards the development of an improved test to aid in the diagnosis of active tuberculosis (TB).

BG Medicine, Inc.

BG Medicine, Inc. Appoints Brian S. Posner to its Board of Directors

BG Medicine, Inc. Appoints Brian S. Posner to its Board of Directors

February 13, 2012

WALTHAM, Mass., February 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced the appointment of  Brian S. Posner to its Board of Directors. Mr.

BG Medicine, Inc.

BG Medicine Announces Positive Pivotal Validation Study Results for CardioSCORE, a New Diagnostic Blood Test to Identify Individuals at High Risk for Near-term Major Cardiovascular Events

BG Medicine Announces Positive Pivotal Validation Study Results for CardioSCORE, a New Diagnostic Blood Test to Identify Individuals at High Risk for Near-term Major Cardiovascular Events

February 13, 2012

Waltham, MA, February 13, 2012 -- BG Medicine, Inc.

T2 Biosystems, Inc.

T2 Biosystems Announces Issuance of Key Patent Providing Broad Intellectual Property Protection for Direct Detection Diagnostic Methods

T2 Biosystems Announces Issuance of Key Patent Providing Broad Intellectual Property Protection for Direct Detection Diagnostic Methods

February 2, 2012

Lexington, MA – T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the issuance of patent number 8,102,176 by the United States Patent and Trademark Office entitled

Joule Unlimited, Inc.

JOULE ELECTS ANATOLY CHUBAIS TO BOARD OF DIRECTORS

JOULE ELECTS ANATOLY CHUBAIS TO BOARD OF DIRECTORS

February 2, 2012

THE RUSSIA FORUM – Moscow, Russia – February 2, 2012 – Joule today announced the election of Anatoly Chubais to its board of directors, adding the expertise and insight of a prominent figure in international business, economics and government. The news was released in conjunction with Joule’s participation at the Russia Forum, an annual meeting of high-profile international economists and business leaders.

Avedro, Inc.

Avedro Announces Canadian Approval for Lasik Xtra™

Avedro Announces Canadian Approval for Lasik Xtra™

January 31, 2012

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. announced today that the Company’s proprietary Lasik Xtra procedure has received Canadian Approval. Lasik Xtra is a two minute procedure used in conjunction with standard Lasik to restore biomechanical integrity and strength to the cornea after a standard Lasik procedure. The procedure combines riboflavin ophthalmic solution with Avedro’s KXL™ System (UVA irradiation) to achieve accelerated corneal cross-linking during a Lasik procedure.